Controversies in NSAIDs Use in Cataract Surgery

Author(s): Mikaella-Anthia Tsangaridou, Andrzej Grzybowski, Enken Gundlach, Uwe Pleyer

Journal Name: Current Pharmaceutical Design

Volume 21 , Issue 32 , 2015

Become EABM
Become Reviewer
Call for Editor


Pseudophakic cystoid macular edema (PCME) remains the most common cause of poor visual outcome following cataract surgery. Whereas acute PCME may resolve itself spontaneously, some patients will suffer from vision impairment and will be difficult to treat. Although PCME has already been described approximately 50 years ago, its pathophysiology remains uncertain and a multitude of mechanisms have been suggested. As broad as the mechanisms, as many are the treatment options. Topical nonsteroidal anti-inflammatory agents (NSAIDs) and corticosteroids either as mono- or combined therapy are a commonly used first line approach. When ineffective, systemic treatment with these agents may be an option. Alternatively, intravitreal application of corticosteroids and anti-vascular endothelial growth factor (anti-VEGF) may offer an effective option, if first-line treatment fails. A critical evaluation of the current literature revealed that the optimal treatment of PCME remains unclear and requires further investigation. In addition, prevention should be of foremost importance and remains an open issue. Identification of risk factors, application of NSAIDs and consequent follow-up are potential essential steps in the avoidance of this complication.

Keywords: Cataract surgery, corticosteroids, nonsteroidal anti-inflammatory agents, pseudophakic cystoid macular edema.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 30 October, 2015
Page: [4707 - 4717]
Pages: 11
DOI: 10.2174/1381612821666150909101804
Price: $65

Article Metrics

PDF: 31